Biohaven’s valuation has dropped from $3.9B to $1.42B, but no revenue and high cash burn still limit its appeal. Read why ...

In July 2025, Inovio Pharmaceuticals conducted a Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with ...

Rimegepant 75 mg for 52 weeks is well tolerated, with no liver safety signals and a sustained reduction in monthly migraine days, a new extension study shows.

Patients with migraine spontaneously described typical symptoms like pain but only revealed cognitive symptoms after being asked further questions, according to a speaker at the American Headache ...